Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

The androgenetic alopecia and hair loss therapeutics market was valued at USD 4.30 Billion in 2025 and is projected to reach USD 10.56 Billion by 2035, growing at a CAGR of 9.40%. Growth is supported by the high prevalence of pattern hair loss in men and women, the approval of Janus kinase inhibitors for alopecia areata, rising preference for non-surgical treatment, and wider use of topical and device-based options at home.

Patent activity spans antiandrogens and 5-alpha reductase inhibitors, minoxidil and other growth stimulants, Janus kinase inhibitors, regenerative therapies based on platelet-rich plasma and follicle stem cells, and light-based and microneedling devices for the scalp. Regulatory validation came from FDA approvals of baricitinib in 2022, ritlecitinib in 2023 and deuruxolitinib in 2024 for alopecia areata, while late-stage trials of topical antiandrogens have encouraged applicants to widen filings on delivery systems and scalp care formulations.

This Androgenetic Alopecia and Hair Loss Therapeutics Patent Landscape Analysis Report provides a structured view of patent filing trends, leading assignees, jurisdictions, technology clusters and competitive positioning across drug, cosmetic, regenerative and device approaches to treating hair loss.

Executive Snapshot

  • Global androgenetic alopecia and hair loss therapeutics market valued at USD 4.30 Billion in 2025
  • Market projected to reach USD 10.56 Billion by 2035
  • Expected CAGR of 9.40% during 2026 - 2035
  • Approximately 500+ patent families analysed across the landscape
  • 20+ androgenetic alopecia and hair loss therapeutics patents were granted in 2025
  • Leading jurisdictions include the United States, China, and South Korea
  • 2,100+ androgenetic alopecia and hair loss therapeutics patents are associated with the United States
  • Major innovation areas include topical antiandrogens that act on the hair follicle without systemic exposure, Janus kinase inhibitors for immune-driven hair loss, regenerative approaches based on platelet-rich plasma and follicle stem cells, and light-based and microneedling devices for the scalp
  • Top assignees include L'Oreal, Cosmo Pharmaceuticals, Amorepacific, Kintor Pharmaceutical, and Kao Corporation
  • The androgenetic alopecia and hair loss therapeutics market is experiencing strong growth, driven by the high prevalence of pattern hair loss, the arrival of approved Janus kinase inhibitors for alopecia areata, and growing consumer demand for non-surgical treatment. Baricitinib became the first systemic therapy approved by the FDA for severe alopecia areata in 2022, and ritlecitinib and deuruxolitinib followed in 2023 and 2024.

  • Patent activity is accelerating, with 20+ androgenetic alopecia and hair loss therapeutics patents granted in 2025, reflecting strong innovation momentum in topical antiandrogens that act on the hair follicle without systemic exposure, Janus kinase inhibitors for immune-driven hair loss, regenerative approaches based on platelet-rich plasma and follicle stem cells, and light-based and microneedling devices for the scalp.

  • Top assignees in the androgenetic alopecia and hair loss therapeutics patent landscape include L'Oreal, Cosmo Pharmaceuticals, Amorepacific, Kintor Pharmaceutical, and Kao Corporation, with the United States, China, and South Korea as the dominant patent jurisdictions.

Androgenetic Alopecia and Hair Loss Therapeutics Market Size, Growth Trends, and Industry Outlook

Hair loss is one of the most common dermatological concerns worldwide, and androgenetic alopecia accounts for the largest share of cases in both men and women. Many men show visible thinning by middle age, and women experience diffuse thinning that often becomes noticeable after menopause. Treatment has long rested on minoxidil and finasteride, yet incomplete response, daily adherence and concern about sexual side effects keep patients looking for alternatives. Autoimmune alopecia areata has gained attention since targeted oral therapies reached the clinic. Demand now spans prescription drugs, cosmetic scalp care, injectable procedures and devices, sold through dermatology clinics, pharmacies, online channels and hair restoration centres.

The market growth is driven by the arrival of targeted therapies and a wider group of patients willing to seek treatment, with FDA approvals of baricitinib in 2022, ritlecitinib in 2023 and deuruxolitinib in 2024 giving alopecia areata its first systemic options. Topical antiandrogens in late-stage trials may offer an alternative to oral finasteride for patients wary of systemic effects. Minoxidil has been available over the counter since the 1990s and finasteride was approved for male pattern hair loss in 1997, so a large base of existing users is already familiar with treatment and open to newer options.

The approval of three Janus kinase inhibitors within three years indicates that immune-driven hair loss is now a commercial drug category, and it encourages sponsors to invest in related mechanisms and topical versions. Long-standing use of minoxidil and finasteride shows that patients will stay on treatment for years, which supports recurring revenue for any product that improves on them. Rising interest in platelet-rich plasma injections and microneedling in clinics points to demand for procedures that patients can book without a prescription course. Home-use light-based caps and combs widen the market beyond clinics, although evidence quality varies, which shapes how quickly payers and physicians accept them.

Total Number of Patents for Androgenetic Alopecia and Hair Loss Therapeutics

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Androgenetic Alopecia and Hair Loss Therapeutics Patent Filing Trends and Innovation Activity

Filing intensity in androgenetic alopecia and hair loss therapeutics follows commercial investment by cosmetic groups and pharmaceutical developers. Beauty companies file steadily on actives, peptides, scalp microbiome products and shampoo formulations because launch cycles are short and brand portfolios are broad. Pharmaceutical developers file in bursts around clinical milestones, with applications on topical antiandrogens, Janus kinase inhibitor formulations and delivery systems clustering near trial starts and readouts. Device makers add applications on light sources, microneedle arrays and treatment protocols as clinic and home-use products multiply. Licensing of clascoterone and the progress of pyrilutamide in China have drawn fresh filings from regional applicants.

More than 500 patent families related to androgenetic alopecia and hair loss therapeutics were identified across the landscape. Filing peaked between roughly 2021 and 2024, when applications on Janus kinase inhibitors, topical antiandrogens and scalp care formulations expanded together. The largest clusters cover antiandrogens and 5-alpha reductase inhibitors, growth stimulants such as minoxidil analogues, and hair growth cosmetics, while regenerative therapies and device-based treatments form a smaller but faster-growing second tier. Older families on finasteride and minoxidil formulations remain numerous because new delivery forms, combinations and dosing regimens continue to be filed, even though the original compounds are long off patent.

The rise in filings on Janus kinase inhibitors and topical antiandrogens closely follows approvals and late-stage trials, showing that clinical progress and growing patient demand are converting directly into patent coverage across drugs, formulations and devices.

Scope of the Androgenetic Alopecia and Hair Loss Therapeutics Patent Landscape Analysis Report

This report analyses patent activity and market trends associated with androgenetic alopecia and hair loss therapeutics across the United States, Europe, China, Japan, South Korea, India and international filings made through the World Intellectual Property Organization (WIPO). Coverage includes drugs, cosmetic actives, regenerative therapies and devices that slow hair loss, restore growth or modify the scalp environment, drawn from national offices and regional authorities. Market context reflects clinical and consumer use in Dermatology Clinics, Hospitals, Hair Restoration Centres, Home Care Consumers and Academic and Research Institutes, linking patent coverage to treatment demand in each region.

The scope includes antiandrogens and 5-alpha reductase inhibitors, vasodilators and growth stimulants, immunomodulators and Janus kinase inhibitors, regenerative and cell-based therapies, and device-based therapies as therapeutic approaches. Formulation and route coverage spans topical solutions and foams, oral therapies, injectable therapies, shampoos and scalp care products, and energy-based devices. Conditions considered are male pattern hair loss, female pattern hair loss, alopecia areata, telogen effluvium, and scarring and other alopecias, and patents are grouped by technology cluster to show where innovation concentrates.

The analysis includes patent activity from multinational beauty and personal care groups, pharmaceutical and dermatology companies developing prescription treatments, and specialist biotechnology firms working on antiandrogens, immunomodulators and cell-based therapies. Device manufacturers producing light-based, laser and microneedling products are covered, as are hair restoration clinics and aesthetic medicine groups that patent procedural methods. Universities, hospital dermatology departments and research institutes that file on follicle biology, stem cell activation and biomarkers of hair loss are also included, together with ingredient suppliers whose filings relate to hair loss actives.

The report will cover the following sections in detail:

Analysis by Therapeutic Approach

  • Antiandrogens and 5-Alpha Reductase Inhibitors
  • Vasodilators and Growth Stimulants
  • Immunomodulators and Janus Kinase Inhibitors
  • Regenerative and Cell-Based Therapies
  • Device-Based Therapies

Analysis by Formulation and Route

  • Topical Solutions and Foams
  • Oral Therapies
  • Injectable Therapies
  • Shampoos and Scalp Care Products
  • Energy-Based Devices

Analysis by Condition Type

  • Male Pattern Hair Loss
  • Female Pattern Hair Loss
  • Alopecia Areata
  • Telogen Effluvium
  • Scarring and Other Alopecias

Global Androgenetic Alopecia and Hair Loss Therapeutics Patent Landscape Analysis

Androgenetic Alopecia and Hair Loss Therapeutics Patent Filing Trend Analysis

The evolution of patent filings for androgenetic alopecia and hair loss therapeutics shows an early period dominated by minoxidil formulations and finasteride-type enzyme inhibitors, followed by a long phase of cosmetic actives and shampoo technologies from consumer brands. From the mid-2010s, filings broadened to topical antiandrogens, stem cell and exosome approaches, and microneedling and low-level light devices. Since 2019, applications on Janus kinase inhibitors for alopecia areata have risen sharply after clinical results became available. Grants of more than 20 patents in 2025 indicate a large base of enforceable rights and a continuing pipeline of new applications.

Patent filings increased at an estimated annual growth rate of approximately 6% between 2020 and 2024. Applications on Janus kinase inhibitors and topical antiandrogens grew fastest, supported by late-stage trial data and regulatory approvals. Regenerative therapy filings expanded steadily as clinics adopted platelet-rich plasma and cell-derived products, while cosmetic actives and shampoo filings grew at a slower pace from a larger base. Applicants increasingly claim combinations, such as an antiandrogen with a growth stimulant, because layered claims are harder for competitors to design around than a single compound.

Leading Companies and Assignee Analysis in the Androgenetic Alopecia and Hair Loss Therapeutics Patent Landscape

Among the players with androgenetic alopecia and hair loss therapeutics patent families, new entrants have been identified, which can be either established companies or startups developing novel technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

L'Oreal

L'Oreal holds one of the largest portfolios in hair care and scalp treatment, covering active ingredients for hair density, anti-hair-fall shampoos and serums, and delivery systems for the scalp. Its Aminexil molecule, used in the Vichy Dercos range, and the Kerastase Densifique and Genesis lines are well-known commercial applications. Most products are sold as cosmetics, so the portfolio relies on cosmetic regulation rather than drug approval pathways, which allows rapid launches across many countries. The intellectual property strategy rests on a steady flow of filings for new active molecules, peptide complexes and formulation technologies, backed by a large in-house research organisation. Commercially, the company is positioned as a leader in both professional salon and dermatological channels, with pharmacy and retail reach that supports scalp care sales.

Cosmo Pharmaceuticals

Cosmo Pharmaceuticals is a specialty pharmaceutical group whose hair loss portfolio is built around clascoterone, a topical antiandrogen that acts locally on the hair follicle with limited systemic exposure. Clascoterone cream is approved by the FDA for acne under the Winlevi brand, and a solution form has been taken through late-stage trials in men with androgenetic alopecia. An established safety dataset from the acne approval supports the hair loss filings. Its intellectual property strategy combines composition and use claims on clascoterone with formulation patents for scalp delivery. Commercially, the company is positioned as a drug developer seeking a prescription alternative to oral finasteride for patients concerned about systemic side effects.

Other companies include Amorepacific, Kintor Pharmaceutical, and Kao Corporation.

The leading assignees, L'Oreal, Cosmo Pharmaceuticals, Amorepacific, Kintor Pharmaceutical and Kao Corporation, hold a visible share of analysed patent families, indicating a fragmented landscape in which consumer brands and drug developers both play a role. L'Oreal and Kao Corporation file on cosmetic actives, scalp care and hair density products, and Amorepacific concentrates on botanical and fermented ingredients for hair loss care. Cosmo Pharmaceuticals protects clascoterone, and Kintor Pharmaceutical pursues antiandrogen candidates such as pyrilutamide. A long tail of universities, clinics and smaller firms adds claims on cell therapies and devices.

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Geographic Analysis of Androgenetic Alopecia and Hair Loss Therapeutics Patent Activity

The report assesses patent activity across major jurisdictions, including:

  • United States
  • Europe
  • China
  • Japan
  • South Korea
  • India
  • International and WIPO filings

The United States is the largest single jurisdiction for androgenetic alopecia and hair loss therapeutics, reflecting the size of its prescription and aesthetics market, the presence of major dermatology developers and the strength of patent enforcement. China follows closely, driven by domestic drug developers, a large consumer base for hair loss products and growing investment in antiandrogen and traditional medicine-derived candidates. South Korea has become a leading filing centre because beauty groups and biotechnology firms treat hair loss care as a priority category. Japan, Europe and India show steady activity linked to cosmetic groups, dermatology research and expanding clinic networks, while WIPO filings show which families applicants intend to take into several markets at once.

Global Androgenetic Alopecia and Hair Loss Therapeutics Patents - Country-wise Analysis for Key Players

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Androgenetic Alopecia and Hair Loss Therapeutics Technology Segmentation and Innovation Areas

The patent landscape is segmented by the technology categories most closely associated with androgenetic alopecia and hair loss therapeutics, which include:

  • Antiandrogens and 5-alpha reductase inhibitors
  • Vasodilators and hair growth stimulants
  • Janus kinase inhibitors and immunomodulators
  • Regenerative and cell-based therapies
  • Light-based and microneedling scalp devices

Among these, antiandrogens and 5-alpha reductase inhibitors account for the largest share of drug-related patent activity. Applicants are filing on topical delivery of finasteride and dutasteride, locally acting androgen receptor antagonists, and combinations that pair an antiandrogen with minoxidil. The aim is to retain efficacy while limiting systemic exposure and the sexual side effects that lead many patients to stop oral therapy. Growth in this cluster has been supported by late-stage trials of clascoterone and pyrilutamide, and every major drug-oriented assignee now maintains active programmes in topical antiandrogens.

Competitive Landscape and Emerging Trends in the Androgenetic Alopecia and Hair Loss Therapeutics Market

The androgenetic alopecia and hair loss therapeutics market is competitive and fragmented, shaped by global beauty groups, pharmaceutical developers and device makers. Competition in cosmetics rests on brand reach, scalp care claims and launch speed, while prescription competition depends on trial data and regulatory approval. Approvals of Janus kinase inhibitors for alopecia areata have drawn large pharmaceutical companies into hair loss, and filings from Chinese and Korean applicants show regional challengers building their own antiandrogen and scalp care portfolios. Positions in topical delivery and combination products will influence who gains share from established minoxidil and finasteride users.

Companies are focusing on:

  • Topical antiandrogens with limited systemic exposure
  • Janus kinase inhibitors for alopecia areata
  • Platelet-rich plasma and follicle stem cells
  • Minoxidil formulations with better tolerability
  • Scalp microbiome and shampoo actives
  • Light-based and microneedling scalp devices
  • Combination regimens for pattern hair loss

Emerging innovation themes include topical Janus kinase inhibitors that aim to treat alopecia areata without systemic exposure, oral low-dose minoxidil regimens, and exosome and peptide products designed to reactivate dormant follicles. Developers are exploring microneedle patches that deliver drugs into the scalp, home-use light devices with better dosing control, and biomarkers that predict which patients will respond to a given therapy. Female pattern hair loss and telogen effluvium are drawing more interest, since many existing drugs were studied mainly in men and women remain underserved in treatment options.

Strategic Insights from the Androgenetic Alopecia and Hair Loss Therapeutics Patent Landscape

The patent landscape for androgenetic alopecia and hair loss therapeutics maps how innovation is distributed across therapeutic approaches, formulations and condition types in more than 500 patent families, and it identifies the assignees and jurisdictions where protection is concentrated. Filings on Janus kinase inhibitors, topical antiandrogens and regenerative therapies show where capital is being directed, while mature minoxidil and finasteride families indicate where freedom to operate depends on formulation claims. Together, the findings give drug developers, beauty groups, investors and clinic operators a structured view of competitive positions.

The landscape provides actionable intelligence for the following nine uses:

  • Intellectual property strategy
  • Research and development prioritisation
  • Competitive benchmarking of hair loss portfolios
  • Technology scouting in topical antiandrogens
  • Licensing evaluation for hair growth actives
  • Partnership assessment with clinic networks
  • Investment analysis of hair loss biotechnology firms
  • Market entry planning by jurisdiction
  • Portfolio expansion across condition types

Research Methodology for the Androgenetic Alopecia and Hair Loss Therapeutics Patent Landscape Analysis

Patent research was conducted across major patent databases, including national and regional office records and international filings published under the Patent Cooperation Treaty. Search strategies combined Cooperative Patent Classification codes for hair treatment, dermatological preparations and scalp devices with keyword queries on antiandrogens, Janus kinase inhibitors, growth stimulants, regenerative therapies and hair loss conditions. Records were gathered through the latest complete publication period, and equivalent filings were consolidated into patent families so that each invention was counted once.

Screening removed duplicate families and filings with no relevance to androgenetic alopecia and hair loss therapeutics. Remaining records were reviewed and classified by technology cluster, therapeutic approach, formulation and route, condition type, assignee and jurisdiction. Assignee names were standardised so that subsidiaries and name variants were attributed to a single owner, and legal status was used to separate granted patents from pending applications.

Market analysis supported the interpretation of patent trends through review of regulatory approvals, clinical trial publications, company disclosures and treatment adoption data. Patent activity was compared with approval timelines and product launches to show how innovation tracks demand. Findings were cross-checked across sources, and analyst estimates are described as approximate where exact counts were not available.

Related Reports

Androgenetic Alopecia Treatment Market

Drug Delivery Devices Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Frequently Asked Questions About This Report

EMR's Androgenetic Alopecia and Hair Loss Therapeutics Patent Landscape Analysis provides a comprehensive assessment of patent filings, innovation clusters, assignee portfolios, and geographic filing patterns across the androgenetic alopecia and hair loss therapeutics landscape. The report identifies 500+ patent families, evaluates leading jurisdictions including the United States, China, and South Korea, and profiles the top assignees by portfolio size.

The global androgenetic alopecia and hair loss therapeutics market was valued at USD 4.30 Billion in 2025. The market is projected to reach USD 10.56 Billion by 2035, expanding at a CAGR of 9.40% during 2026 - 2035.

The report analyses approximately 500+ patent families related to androgenetic alopecia and hair loss therapeutics. These include filings from the United States, China, South Korea, and international WIPO filings.

Key companies operating within the landscape include L'Oreal, Cosmo Pharmaceuticals, Amorepacific, Kintor Pharmaceutical, and Kao Corporation, among others. These organisations collectively account for a significant portion of patent activity analysed in this report.

The report evaluates patent activity across the United States, Europe, China, Japan, South Korea, India, and international WIPO filings. The United States is the largest single jurisdiction for androgenetic alopecia and hair loss therapeutics, with 2,100+ patents associated with it across the 500+ patent families analysed.

Yes. The report scope can be customised based on geography, technology segment, assignee selection, time period, or specific innovation cluster focus. Readers can contact the EMR team to scope a customised study, such as a tailored patent landscape focused on topical antiandrogens, Janus kinase inhibitors or regenerative therapies for hair loss, or on particular assignees and jurisdictions.

Patent landscape analysis helps organisations understand innovation trends, competitive activity, technology whitespace, and IP risk across a defined domain. For androgenetic alopecia and hair loss therapeutics, this report supports strategic decisions in R&D prioritisation, licensing evaluation, competitive benchmarking, and market entry planning.

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Analysis by Therapeutic Approach

  • Antiandrogens and 5-Alpha Reductase Inhibitors
  • Vasodilators and Growth Stimulants
  • Immunomodulators and Janus Kinase Inhibitors
  • Regenerative and Cell-Based Therapies
  • Device-Based Therapies

Analysis by Formulation and RouteAnalysis by Formulation and Route

  • Topical Solutions and Foams
  • Oral Therapies
  • Injectable Therapies
  • Shampoos and Scalp Care Products
  • Energy-Based Devices

Analysis by Condition Type

  • Male Pattern Hair Loss
  • Female Pattern Hair Loss
  • Alopecia Areata
  • Telogen Effluvium
  • Scarring and Other Alopecias

Analysis by End User

  • Dermatology Clinics
  • Hospitals
  • Hair Restoration Centres
  • Home Care Consumers
  • Academic and Research Institutes

Key Players Mentioned

  • L'Oreal
  • Cosmo Pharmaceuticals
  • Amorepacific
  • Kintor Pharmaceutical
  • Kao Corporation

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Mini Report

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us